Information on the target
MIR – Medical International Research is a prominent player in the spirometry sector, specializing in the development and manufacturing of innovative biomedical devices. The company has established a strong reputation for delivering high-quality products that enhance respiratory diagnostics and patient care. With a commitment to research and development, MIR has consistently pushed the boundaries of technology in the biomedical field, positioning itself as a leader in the industry.
The recent acquisition of MIR by Quadrivio’s Silver Economy Fund, along with a consortium of co-investors, marks a significant milestone for the company. This transaction not only reflects the confidence in MIR's growth potential but also ensures that the existing management team, including the newly appointed CEO Roberta Di Pinto and CTO Adriano Mencarini, will continue to drive the company's strategic vision forward.
Industry overview in the target’s specific country
The biomedical devices industry in Italy has witnessed substantial growth over the past decade, driven by advancements in technology and an increasing demand for innovative healthcare solutions. Italy is recognized as one of the leading countries in Europe for medical device manufacturing, with a robust ecosystem that includes research institutions, universities, and a skilled workforce. The Italian biomedical sector is characterized by a diverse range of products, including diagnostic equipment, therapeutic devices, and surgical instruments.
In recent years, the Italian government has implemented various initiatives to support the biomedical industry, including funding for research and development, tax incentives for innovation, and streamlined regulatory processes. These measures have fostered an environment conducive to growth, enabling companies like MIR to thrive and expand their market presence both domestically and internationally.
Moreover, the aging population in Italy has led to an increased focus on healthcare services, driving demand for advanced medical devices that improve patient outcomes. The rise in chronic diseases and respiratory conditions has further emphasized the need for effective diagnostic tools, positioning companies like MIR at the forefront of addressing these healthcare challenges. As a result, the Italian biomedical devices market is expected to continue its upward trajectory, presenting significant opportunities for investment and growth.
The rationale behind the deal The sale of MIR to Quadrivio’s Silver Economy Fund aligns with Aksìa's strategic vision of supporting the growth and internationalization of its portfolio companies. This transaction not only provides a successful exit for Aksìa Capital V …